FDA Maintains Clinical Hold on Larimar’s Friedreich’s Ataxia Study

Global Genes. February 15, 2022. Larimar Therapeutics, a company focused on developing treatments for complex rare diseases, said that the U.S. Food and Drug Administration is maintaining the clinical hold on Larimar’s CTI-1601 program for the treatment of Friedreich’s ataxia.

FDA Maintains Clinical Hold on Larimar’s Friedreich’s Ataxia Study